RESUMEN
Methionine aminopeptidase-2 (MetAP2) processes N-terminal methionine from nascent cellular proteins. Inhibition of MetAP2 has been shown to block angiogenesis and suppress tumor growth in preclinical tumor models. However, the biological role of MetAP2 in cancer is not well understood. We examined the effect of three distinct chemical classes of MetAP2 inhibitors on the growth of a panel of human cancer cells in vitro. All MetAP2 inhibitors caused inhibition of tumor cell growth in both anchorage-dependent and, particularly, in anchorage-independent manner. These data prompted us to examine the possible roles of MetAP2 in cancers. Ectopic expression of MetAP2 in NIH-3T3 cells caused transformation, evidenced by the formation of foci in monolayer culture and growth of large colonies in soft agar. Overexpression of MetAP2 in an immortalized bronchial epithelial cell line NL20 accelerated growth. These phenotypes induced by the overexpression of MetAP2 were reversed by the treatment with MetAP2 inhibitors, indicating that the catalytic function of MetAP2 was essential. Accordingly, overexpression of a catalytically inactive MetAP2 resulted in growth retardation of HT1080 tumor cells, suggesting a dominant-negative role of the inactive MetAP2 mutant. Finally, we analysed the expression of MetAP2 in patient cancer samples by immunohistochemistry. Moderate-to-high staining was identified in the majority of breast, colon, lung, ovarian and prostate carcinomas examined. These data suggest that MetAP2 plays an important role in tumor cell growth and may contribute to tumorigenesis.
Asunto(s)
Aminopeptidasas/biosíntesis , Transformación Celular Neoplásica , Regulación Enzimológica de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Metaloendopeptidasas/biosíntesis , Animales , Catálisis , Línea Celular Tumoral , Proliferación Celular , Genes Dominantes , Humanos , Inmunohistoquímica , Ratones , Células 3T3 NIH , Fenotipo , Estructura Terciaria de ProteínaRESUMEN
Internal tandem duplications (ITDs) of fms-like tyrosine kinase 3 (FLT3) receptor play an important role in the pathogenesis of acute myeloid leukemia (AML) and represent an attractive therapeutic target. ABT-869 has demonstrated potent effects in AML cells with FLT3-ITDs. Here, we provide further evidence that ABT-869 treatment significantly downregulates cyclins D and E but increases the expression of p21 and p27. ABT-869 induces apoptosis through downregulation of Bcl-xL and upregulation of BAK, BID and BAD. We also evaluate the combinations of ABT-869 and chemotherapy. ABT-869 demonstrates significant sequence-dependent synergism with cytarabine and doxorubicin in cell lines and primary leukemia samples. The optimal combination was validated in MV4-11 xenografts. Low-density array analysis revealed the synergistic interaction involved in downregulation of cell cycle and mitogen-activated protein kinase pathway genes. CCND1 and c-Mos were the most significantly inhibited targets on both transcriptional and translational levels. Treatment with short hairpin RNAs targeting either CCND1 or c-Mos further sensitized MV4-11 cells to ABT-869. These findings suggest that specific pathway genes were further targeted by adding chemotherapy and support the rationale of combination therapy. Thus, a clinical trial using sequence-dependent combination therapy with ABT-869 in AML is warranted.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Proteínas de Ciclo Celular/metabolismo , Indazoles/uso terapéutico , Leucemia Mieloide/tratamiento farmacológico , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Compuestos de Fenilurea/uso terapéutico , Proteínas Proto-Oncogénicas c-mos/metabolismo , Transducción de Señal/efectos de los fármacos , Enfermedad Aguda , Animales , Apoptosis/efectos de los fármacos , Proteínas de Ciclo Celular/genética , Citarabina/administración & dosificación , Regulación hacia Abajo , Doxorrubicina/administración & dosificación , Sinergismo Farmacológico , Quimioterapia Combinada , Perfilación de la Expresión Génica , Humanos , Leucemia Mieloide/metabolismo , Leucemia Mieloide/patología , Ratones , Ratones SCID , Proteínas Proto-Oncogénicas c-mos/genética , ARN Interferente Pequeño/farmacología , Proteínas Tirosina Quinasas Receptoras/antagonistas & inhibidores , Trasplante HeterólogoRESUMEN
Histone deacetylase (HDAC) inhibitors induce the hyperacetylation of nucleosomal histones in carcinoma cells resulting in the expression of repressed genes that cause growth arrest, terminal differentiation, and/or apoptosis. In vitro selectivity of several novel hydroxamate HDAC inhibitors including succinimide macrocyclic hydroxamates and the non-hydroxamate alpha-ketoamide inhibitors was investigated using isolated enzyme preparations and cellular assays. In vitro selectivity for the HDAC isozymes (HDAC1/2, 3, 4/3, and 6) was not observed for these HDAC inhibitors or the reference HDAC inhibitors, MS-275 and SAHA. In T24 and HCT116 cells these compounds caused the accumulation of acetylated histones H3 and H4; however, the succinimide macrocyclic hydroxamates and the alpha-ketoamides did not cause the accumulation of acetylated alpha-tubulin. These data suggest "selectivity" can be observed at the cellular level with HDAC inhibitors and that the nature of the zinc-chelating moiety is an important determinant of activity against tubulin deacetylase.
Asunto(s)
Amidas/farmacología , Neoplasias de la Mama/enzimología , Fibrosarcoma/enzimología , Inhibidores de Histona Desacetilasas , Histona Desacetilasas/metabolismo , Ácidos Hidroxámicos/farmacología , Amidas/química , Neoplasias de la Mama/patología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Activación Enzimática/efectos de los fármacos , Inhibidores Enzimáticos , Fibrosarcoma/patología , Histona Desacetilasas/química , Humanos , Ácidos Hidroxámicos/químicaRESUMEN
A novel series of biaryl ether reverse hydroxamate MMP inhibitors has been developed. These compounds are potent MMP-2 inhibitors with limited activity against MMP-1. Select members of this series exhibit excellent pharmacokinetic properties with long elimination half-lives (7 h) and high oral bioavailability (100%).
Asunto(s)
Ácidos Hidroxámicos/síntesis química , Inhibidores de la Metaloproteinasa de la Matriz , Administración Oral , Animales , Antineoplásicos/sangre , Antineoplásicos/síntesis química , Antineoplásicos/farmacocinética , Disponibilidad Biológica , Inhibidores Enzimáticos/sangre , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/farmacocinética , Semivida , Ácidos Hidroxámicos/química , Concentración 50 Inhibidora , Inyecciones Intravenosas , Macaca fascicularisRESUMEN
Modification of the biphenyl portion of MMP inhibitor 2a gave analogue 2i which is greater than 1000-fold selective against MMP-2 versus MMP-1. The stereospecific synthesis of both enantiomers of 2i was achieved beginning with (S)- or (R)-benzyl glycidyl ether. The (S)-enantiomer, 11 (ABT-770), is orally bioavailable and efficacious in an in vivo model of tumor growth.
Asunto(s)
Compuestos de Bifenilo/farmacocinética , Ácidos Hidroxámicos/farmacocinética , Inhibidores de la Metaloproteinasa de la Matriz , Administración Oral , Animales , Antineoplásicos/sangre , Antineoplásicos/síntesis química , Antineoplásicos/farmacocinética , Área Bajo la Curva , Disponibilidad Biológica , Compuestos de Bifenilo/sangre , Compuestos de Bifenilo/síntesis química , División Celular/efectos de los fármacos , Perros , Inhibidores Enzimáticos/sangre , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/farmacocinética , Semivida , Haplorrinos , Ácidos Hidroxámicos/sangre , Ácidos Hidroxámicos/síntesis química , Concentración 50 Inhibidora , Inyecciones Intravenosas , Tasa de Depuración Metabólica , Neoplasias Experimentales/tratamiento farmacológico , Ratas , Relación Estructura-Actividad , Células Tumorales CultivadasRESUMEN
ABT-770 [(S)-N-[1-[[4'-trifluoromethoxy-[1,1'-biphenyl]-4-yl]oxy]methyl-2-(4,4-dimethyl-2,5-dioxo-1-imidazolidinyl)ethyl]-N-hydroxyformamide], a matrix metalloproteinase inhibitor (MMPI), produced generalized phospholipidosis in rats. Phospholipid accumulation was accompanied by retention of drug-related material and was associated with increased mortality. Generation of a successful drug candidate depended upon understanding the cause of the phospholipidosis and redesigning the chemical structure accordingly. ABT-770 and other MMPIs, plus several metabolites of each, were assayed for their ability to induce phospholipidosis in primary cultured rat and human hepatocytes. Phospholipid accumulation was detected by following the incorporation of a fluorescent phospholipid analogue into intracytoplasmic inclusion bodies characteristic of phospholipid storage disorders. At 24 and 48 hr, none of the parent compounds induced phospholipidosis in vitro in rat or human hepatocytes. Phospholipidosis was associated primarily with an amine metabolite of ABT-770. The amine metabolite of another MMPI, ABT-518 ([S-(R*,R*)]-N-[1-(2,2-dimethyl-1,3-dioxol-4-yl)-2-[[4-[4-(trifluoromethoxy)-phenoxy]phenyl]sulfonyl]ethyl]-N-hydroxyformamide), produced little phospholipidosis in rat and human hepatocytes even at concentrations up to 100 microM. The presence or absence of phospholipidosis in the in vitro assay correlated well with ultrastructural findings and drug accumulation in rat tissues. ABT-770, which produced phospholipidosis associated with its amine metabolite in vitro and in vivo, also generated a higher tissue to plasma distribution of metabolites particularly in tissues where phospholipidosis was observed. ABT-518 and its amine metabolite, however, produced low tissue to plasma ratios and induced little to no phospholipidosis in vitro or in vivo. These results demonstrate that the phospholipidosis observed for ABT-770 could be attributed to a cationic metabolite, and that altering the properties of such a metabolite, by modification of the parent compound, alleviated the disorder.
Asunto(s)
Compuestos de Bifenilo/efectos adversos , Hepatocitos/efectos de los fármacos , Ácidos Hidroxámicos/efectos adversos , Lipidosis/inducido químicamente , Inhibidores de la Metaloproteinasa de la Matriz , Animales , Compuestos de Bifenilo/metabolismo , Formamidas/metabolismo , Formamidas/farmacología , Inhibidores de la Proteasa del VIH/efectos adversos , Inhibidores de la Proteasa del VIH/metabolismo , Hepatocitos/metabolismo , Humanos , Ácidos Hidroxámicos/metabolismo , Masculino , Metaloproteinasas de la Matriz/metabolismo , Ratas , Ratas Sprague-DawleyRESUMEN
The matrix metalloproteinases (MMPs) are a family of tightly regulated proteases that are involved in the catabolic aspect of remodeling and maintenance of normal tissue, and more than 20 human MMPs have been identified thus far. The MMPs collectively degrade a broad range of protein components of the extracellular matrix. While some substrate overlap exists, individual MMPs have been shown to process certain substrates more efficiently than others. These differences raise the critical issue of whether broad-spectrum inhibitors, active against all MMPs, or selective inhibitors, targeted to a subset of enzymes, represent the optimal therapeutic strategy for a given disease. This suggests the need to assess the inhibition potency of test compounds across a range of MMP family members. Described in this unit is a method for the in vitro characterization of MMP inhibitors. The is used to determine the potency of test compounds as inhibitors of 8 representative MMPs through the measurement of their inhibition of cleavage of a fluorogenic substrate. Since this substrate is efficiently hydrolyzed by all MMPs in the screening assays presented here, the method is convenient for assessing the selectivity of inhibitors against multiple enzymes. A describes the activation of MMP zymogens.
Asunto(s)
Pruebas de Enzimas/métodos , Inhibidores de la Metaloproteinasa de la Matriz , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/farmacología , Humanos , Metaloproteinasas de la Matriz/metabolismoRESUMEN
Since the matrix metalloproteinases (MMPs) have an essential role in the process of tumor growth, invasion and metastasis, small molecule MMP inhibitors have the ability to modulate tumor progression in animals and the potential to be of therapeutic benefit to cancer patients. The antiangiogenic properties of MMP inhibitors can be assessed by the measurement of hemoglobin content of Matrigel plugs containing angiogenic growth factors introduced into the flanks of mice. A flank tumor growth model using B16 murine melanoma cells provides a useful means of determining the antitumor effects of MMP inhibitors as well as correlating efficacy with the concentration of drug in blood.
Asunto(s)
Inhibidores de la Angiogénesis/uso terapéutico , Inhibidores de la Metaloproteinasa de la Matriz , Neovascularización Patológica/tratamiento farmacológico , Ensayos Antitumor por Modelo de Xenoinjerto/métodos , Inhibidores de la Angiogénesis/farmacología , Animales , Inhibidores Enzimáticos/farmacología , Inhibidores Enzimáticos/uso terapéutico , Femenino , Humanos , Metaloproteinasas de la Matriz/metabolismo , Melanoma Experimental/tratamiento farmacológico , Melanoma Experimental/enzimología , Ratones , Ratones Endogámicos C57BL , Neovascularización Patológica/enzimologíaRESUMEN
Members of the matrix metalloprotease (MMP) family are implicated in the progression of several malignancies including prostate cancer due to their ability to break down extracellular matrix (ECM) components. In this study, we have evaluated the ability of a synthetic MMP inhibitor (A-177430) to block tumor growth and metastases in a syngeneic model of rat prostate cancer. In an in vitro substrate assay, A-177430 exhibited nanomolar potency (IC(50) 2-6 nM) against the enzymatic activity of several MMPs. For in vivo studies, male Copenhagen rats were injected s.c. with Mat Ly Lu rat prostate cancer cells (1 x 10(6) cells ) into the right flank and animals were administered i.p.with different doses (10-100 mg/kg per day) of A-177430 for 16 days. Administration of A-177430 resulted in a dose-dependent decrease in tumor volume as compared to a control group of animals receiving vehicle alone. The maximum dose (100 mg/kg per day) of A-177430 exhibited complete arrest in tumor growth and prevented the development of macroscopic tumor metastases to lungs without exhibiting any noticeable side effects. Histologic examination of primary tumors from experimental animals showed extensive tumor necrosis and decreased tumor angiogenesis as determined by factor VIII staining of primary tumors following A-177430 treatment. These primary tumors from experimental animals also exhibited a significant increase in tumor cell DNA fragmentation as determined by TUNEL assay. Collectively, these results demonstrate the ability of MMP inhibitors to block tumor growth and metastases by blocking ECM degradation and by inhibiting tumor angiogenesis and promotion of prostate cancer cell apoptosis in vivo.
Asunto(s)
Inhibidores Enzimáticos/farmacología , Inhibidores de la Metaloproteinasa de la Matriz , Metástasis de la Neoplasia , Péptidos Cíclicos/farmacología , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/patología , Animales , División Celular/efectos de los fármacos , Colágeno/metabolismo , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Inmunohistoquímica , Etiquetado Corte-Fin in Situ , Laminina/metabolismo , Masculino , Trasplante de Neoplasias , Péptidos Cíclicos/química , Proteoglicanos/metabolismo , Ratas , Ratas Endogámicas , Factores de Tiempo , Distribución Tisular , Células Tumorales CultivadasRESUMEN
Two series of compounds synthesized as specific matrix metalloproteinase (MMP) inhibitors have been evaluated for their inhibition of non-MMPs. In a series of substituted succinyl hydroxamic acids, some were found to be significant (IC50 < 1 microM) inhibitors of leucine (microsomal) aminopeptidase, neprilysin (3.4.24.11), and thermolysin. Macrocyclic compounds in which the alpha carbon of the succinyl hydroxamate is linked to the side chain of the P2' amino acid were found to be good inhibitors of aminopeptidase, but not of neprilysin or thermolysin. Compounds of neither series were found to be significant inhibitors of angiotensin converting enzyme or carboxypeptidase A.
Asunto(s)
Inhibidores de la Metaloproteinasa de la Matriz , Metaloendopeptidasas/antagonistas & inhibidores , Inhibidores de la Enzima Convertidora de Angiotensina , Animales , Proteínas Bacterianas , Carboxipeptidasas/antagonistas & inhibidores , Carboxipeptidasas A , Bovinos , Ácidos Hidroxámicos/síntesis química , Ácidos Hidroxámicos/metabolismo , Concentración 50 Inhibidora , Leucil Aminopeptidasa/antagonistas & inhibidores , Neprilisina/antagonistas & inhibidores , Inhibidores de Proteasas/síntesis química , Inhibidores de Proteasas/química , Inhibidores de Proteasas/metabolismo , Conejos , Ratas , Porcinos , Termolisina/antagonistas & inhibidores , Zinc/metabolismoRESUMEN
Platelet-activating factor (PAF) may be an important mediator of allergic rhinitis. In the present study we evaluated the effectiveness of a recently described PAF antagonist (ABT-491) in rat and guinea pig models of allergic rhinitis. PAF, when perfused through the nasal passages of anesthetized Brown Norway rats, provoked an acute increase, measured as dye leakage, in nasal vascular permeability evident within 15 min after exposure to PAF. ABT-491, given orally 1 hr before PAF challenge, inhibited the response in a dose-related manner (ED50 = 0.3 mg/kg). Intranasal perfusion with ovalbumin in rats sensitized to the antigen 18 to 21 days before challenge also induced an increase in vascular permeability. The antigen-induced leakage was inhibited a maximum of 74% (P < or = .001) by pretreatment with ABT-491 (3 mg/kg p.o.). An antihistamine (mepyramine, 10 mg/kg i.p.), a serotonin antagonist (methysergide) and a 5-lipoxygenase inhibitor (A-79175) also exhibited efficacy in this model (56%, 87% and 65% inhibition, respectively). Nearly complete inhibition (93%, P < or = .001) of the response was achieved by coadministration of ABT-491 and methysergide. In guinea pigs intranasal administration of PAF resulted in increased airway resistance that was inhibited in a dose-dependent manner by oral administration of ABT-491 (ED50 = 1 mg/kg). Antigen-induced nasal airway resistance, triggered by exposure of sensitized animals to aerosolized ovalbumin, was also inhibited by ABT-491 (maximum inhibition 64%, P < or = .05, 10 mg/kg p.o.). The effectiveness of the antagonist was increased to 80% protection by coadministration with either an antihistamine or a 5-lipoxygenase inhibitor, agents which were separately insignificant in blocking the response to antigen. These results suggest a therapeutic utility for ABT-491, perhaps in combination with other anti-inflammatory agents, in the treatment of allergic rhinitis.
Asunto(s)
Hipersensibilidad/tratamiento farmacológico , Imidazoles/farmacología , Indoles/farmacología , Factor de Activación Plaquetaria/antagonistas & inhibidores , Rinitis/tratamiento farmacológico , Resistencia de las Vías Respiratorias/efectos de los fármacos , Animales , Permeabilidad Capilar/efectos de los fármacos , Cobayas , Masculino , Factor de Activación Plaquetaria/fisiología , Ratas , Ratas Endogámicas BNRESUMEN
Studies conducted with the goal of discovering a second-generation platelet-activating factor (PAF) antagonist have identified a novel class of potent and orally active antagonists which have high aqueous solubility and long duration of action in animal models. The compounds arose from the combination of the lipophilic indole portion of Abbott's first-generation PAF antagonist ABT-299 (2) with the methylimidazopyridine heterocycle moiety of British Biotechnology's BB-882 (1) and possess the positive attributes of both of these clinical candidates. Structure-activity relationship (SAR) studies indicated that modification of the indole and benzoyl spacer of lead compound 7b gave analogues that were more potent, longer-lived, and bioavailable and resulted in the identification of 1-(N, N-dimethylcarbamoyl)-4-ethynyl-3-[3-fluoro-4-[(1H-2-methylimidazo[4,5-c] pyrid-1-yl)methyl]benzoyl]indole hydrochloride (ABT-491, 22 m.HCl) which has been evaluated extensively and is currently in clinical development.
Asunto(s)
Imidazoles/síntesis química , Factor de Activación Plaquetaria/antagonistas & inhibidores , Inhibidores de Agregación Plaquetaria/síntesis química , Glicoproteínas de Membrana Plaquetaria/metabolismo , Piridinas/síntesis química , Receptores de Superficie Celular , Receptores Acoplados a Proteínas G , Animales , Disponibilidad Biológica , Plaquetas/efectos de los fármacos , Plaquetas/fisiología , Permeabilidad Capilar/efectos de los fármacos , Perros , Femenino , Cobayas , Humanos , Imidazoles/química , Imidazoles/farmacología , Macaca fascicularis , Masculino , Estructura Molecular , Factor de Activación Plaquetaria/farmacología , Inhibidores de Agregación Plaquetaria/química , Inhibidores de Agregación Plaquetaria/farmacocinética , Inhibidores de Agregación Plaquetaria/farmacología , Piridinas/química , Piridinas/farmacocinética , Piridinas/farmacología , Ratas , Ratas Sprague-Dawley , Relación Estructura-ActividadRESUMEN
A series of P1 C alpha gem-disubstituted succinamide hydroxamate matrix metalloproteinase inhibitors were prepared stereoselectively and evaluated in vitro for their ability to inhibit MMP-1, MMP-2, and MMP-3. It was found that while methyl/allyl substitution as in 2 and 18 provided compounds that were broad spectrum inhibitors and nearly equipotent with parent inhibitor 1, a larger group such as bis-allyl as in 13 or gem-cyclopentyl as in 14 significantly reduced enzyme inhibition.
Asunto(s)
Ácidos Hidroxámicos/farmacología , Metaloendopeptidasas/antagonistas & inhibidores , Inhibidores de Proteasas/farmacología , Animales , Ácidos Hidroxámicos/química , Ácidos Hidroxámicos/farmacocinética , Modelos Moleculares , Estructura Molecular , Inhibidores de Proteasas/química , Inhibidores de Proteasas/farmacocinética , RatasRESUMEN
A series of succinate-derived hydroxamic acids incorporating a macrocyclic ring were designed, synthesized, and evaluated as inhibitors of matrix metalloproteinases. The inhibitors were designed based on the published X-ray crystal structure of batimastat (1) complexed with human neutrophil collagenase (MMP-8). The synthesized compounds were shown to inhibit selected MMPs in vitro with low nanomolar potency.
Asunto(s)
Colagenasas/química , Ácidos Hidroxámicos/síntesis química , Inhibidores de la Metaloproteinasa de la Matriz , Fenilalanina/análogos & derivados , Inhibidores de Proteasas/síntesis química , Tiofenos/química , Tiofenos/síntesis química , Cristalografía por Rayos X , Diseño de Fármacos , Humanos , Ácidos Hidroxámicos/química , Ácidos Hidroxámicos/farmacología , Indicadores y Reactivos , Cinética , Metaloproteinasa 8 de la Matriz , Modelos Moleculares , Fenilalanina/química , Fenilalanina/farmacología , Inhibidores de Proteasas/química , Inhibidores de Proteasas/farmacología , Relación Estructura-Actividad , Succinatos/síntesis química , Succinatos/química , Succinatos/farmacología , Tiofenos/farmacologíaRESUMEN
A series of succinyl hydroxamate MMP inhibitors were prepared incorporating an aryl amino ketone moiety in place of the more typical C-terminal amino acid amides. Compounds of the C-terminal ketone series displayed potent inhibition of MMPs. Several compounds of the series were shown to be orally bioavailable.
Asunto(s)
Gelatinasas/antagonistas & inhibidores , Ácidos Hidroxámicos/farmacología , Cetonas/farmacología , Inhibidores de la Metaloproteinasa de la Matriz , Metaloendopeptidasas/antagonistas & inhibidores , Inhibidores de Proteasas/farmacología , Metaloproteinasa 1 de la Matriz , Metaloproteinasa 2 de la Matriz , Metaloproteinasa 7 de la Matriz , Relación Estructura-ActividadAsunto(s)
Permeabilidad Capilar/efectos de los fármacos , Imidazoles/farmacología , Indoles/farmacología , Mucosa Nasal/irrigación sanguínea , Factor de Activación Plaquetaria/antagonistas & inhibidores , Rinitis Alérgica Perenne/fisiopatología , Animales , Cinética , Factor de Activación Plaquetaria/farmacología , Ratas , Ratas Endogámicas BNRESUMEN
ABT-491 (4-ethynyl-N, N-dimethyl-3-[3-fluoro-4-[(2-methyl-1H-imidazo-[4,5-c]pyridin-1-yl)methy l]benzoyl]-1H- indole-1-carboxamide hydrochloride) is a novel PAF (platelet-activating factor) receptor antagonist with a K(i) for inhibiting PAF binding to human platelets of 0.6 nM. Binding kinetics of ABT-491 to the PAF receptor is consistent with a relatively slow off-rate of the antagonist when compared to PAF. Inhibition of PAF binding is selective and is correlated with functional antagonism of PAF-mediated cellular responses (Ca2+ mobilization, priming, and degranulation). Administration of ABT-491 in vivo leads to potent inhibition of PAF-induced inflammatory responses (increased vascular permeability, hypotension, and edema) and PAF-induced lethality. Oral potency (ED50) was between 0.03 and 0.4 mg/kg in rat, mouse, and guinea-pig. When administered intravenously in these species, ABT-491 exhibited ED50 values between 0.005 and 0.016 mg/kg. An oral dose of 0.5 mg/kg in rat provided > 50% protection for 8 h against cutaneous PAF challenge. ABT-491 administered orally was also effective in inhibiting lipopolysaccharide-induced hypotension (ED50 = 0.04 mg/kg), gastrointestinal damage (0.05 mg/kg, 79% inhibition), and lethality (1 mg/kg, 85% vs. 57% survival). The potency of this novel antagonist suggests that ABT-491 will be useful in the treatment of PAF-mediated diseases.
Asunto(s)
Imidazoles/farmacología , Indoles/farmacología , Glicoproteínas de Membrana Plaquetaria/antagonistas & inhibidores , Receptores de Superficie Celular , Receptores Acoplados a Proteínas G , Enfermedad Aguda , Animales , Plaquetas/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Endotoxemia/tratamiento farmacológico , Cobayas , Humanos , Inflamación/inducido químicamente , Inflamación/tratamiento farmacológico , Lipopolisacáridos/toxicidad , Masculino , Ratones , Ratones Endogámicos ICR , Neutrófilos/efectos de los fármacos , Factor de Activación Plaquetaria/antagonistas & inhibidores , Factor de Activación Plaquetaria/efectos de los fármacos , Factor de Activación Plaquetaria/metabolismo , Glicoproteínas de Membrana Plaquetaria/metabolismo , Conejos , Ratas , Choque/inducido químicamente , Choque/tratamiento farmacológicoRESUMEN
ABT-299, a highly potent and selective platelet activating factor (PAF) antagonist, was found to be effective in rat models of endotoxic shock. ABT-299 inhibited and reversed LPS-induced hypotension (ED50 of .008 mg/kg, intraarterially). When given prior to LPS challenge, ABT-299 (.1 mg/kg, intravenously) completely inhibited LPS-induced intestinal damage for as long as 8 h after the administration of the antagonist. Pretreatment of rats with ABT-299 (5 mg/kg, intravenously over 4 h) prevented by 85-95% symptoms of disseminated intravascular coagulation (DIC) induced by LPS, including thrombocytopenia, prolongation of prothrombin and partial thromboplastin time, decreased serum fibrinogen, and elevation of serum fibrinogen/fibrin degradation products. A .1 mg/kg dose of ABT-299 administered orally or intravenously improved long-term survival to 80% and 90%, respectively, following a lethal dose (LD65) of LPS. ABT-299 (.1 mg/kg) was also effective in preventing hypotension and gastrointestinal damage induced by lipoteichoic acid (LTA), a putative causative agent of shock in Gram-positive infections. These results illustrate the impressive potency and duration of action of ABT-299 and support the putative role of PAF in acute models of endotoxic shock.
Asunto(s)
Endotoxemia/tratamiento farmacológico , Factor de Activación Plaquetaria/antagonistas & inhibidores , Inhibidores de Agregación Plaquetaria/uso terapéutico , Compuestos de Piridinio/uso terapéutico , Tiazoles/uso terapéutico , Animales , Estado de Conciencia , Coagulación Intravascular Diseminada/etiología , Coagulación Intravascular Diseminada/prevención & control , Endotoxemia/complicaciones , Endotoxemia/fisiopatología , Endotoxinas/toxicidad , Hemorragia Gastrointestinal/etiología , Hemorragia Gastrointestinal/prevención & control , Hipotensión/tratamiento farmacológico , Hipotensión/etiología , Hipotensión/prevención & control , Lipopolisacáridos/toxicidad , Masculino , Factor de Activación Plaquetaria/fisiología , Inhibidores de Agregación Plaquetaria/farmacología , Compuestos de Piridinio/farmacología , Ratas , Ratas Sprague-Dawley , Ácidos Teicoicos/toxicidad , Tiazoles/farmacologíaRESUMEN
ABT-299 is an aqueous soluble prodrug that is converted rapidly in vivo to A-85783, a novel, highly potent, specific platelet activating factor (PAF) antagonist. The K, for inhibiting PAF binding to rabbit platelet membranes is 3.9 and 0.3 nM for human platelets. Inhibition is selective and reversible and is correlated with functional antagonism of PAF-mediated cellular responses (calcium mobilization, priming of superoxide generation, aggregation and degranulation). The in vivo generation of A-85783 from ABT-299 leads to potent inhibition of PAF-induced inflammatory responses (increased vascular permeability, hypotension and edema) and PAF-induced lethality. When administered i.v., the potency (ED50) of ABT-299 for inhibiting PAF responses was between 6 to 10 micrograms/kg in the rat and mouse and 100 micrograms/kg in the guinea pig. A dose of 100 micrograms/kg in the rat provided greater than 60% protection for 8 to 16 hr against cutaneous and systemic PAF challenge. This duration was also evidenced by ex vivo inhibition of platelet aggregation in guinea pig and sheep. In addition to being active parenterally, ABT-299 exhibited p.o. activity in the rat and mouse (ED50 = 100 micrograms/kg in both species). Pharmacokinetic studies in the rat revealed that ABT-299 was converted rapidly to A-85783 and, in turn, metabolized to the corresponding pyridine-N-oxide and sulfoxide metabolites. These metabolites exhibited significant potency in vitro and in vivo and thus may contribute to the activity observed after administration of ABT-299.